## **Supplementary information**

**Inactivating mutations and crystal structure of the tumor suppressor OPCML reveal** 

**new cancer-associated functions**

JR Birtley, M Alomary et al.







**Supplementary Figure 1. OPCML is mutated in different tumor types. (A)** The graph shows the percentage of patients who present mutations in the OPCML gene (y-axis) classified per cancer type. The numbers in brackets on the x-axis indicate the total number of patients for each cancer type, while the numbers above the bars show the actual number of patients who have mutations. **(B)** The table indicates the actual number and the relative percentage of the residues present in OPCML, the mutations identified in the databases and the amino acids mutated in the different domains of OPCML.



**Supplementary Figure 2. Topology diagrams of domains 1, 2 and 3 from OPCML.** Domain 1, shown in salmon, belongs to the V-set subfamily of Ig domains and consists of nine β-strands. The AGFCC′ forms one sheet and BED the other. Strand A is displaced somewhat because the C-terminal end from a neighboring molecule (residues 315-9) inserts between the B and G strands to make crystal contacts. Domain 2 (blue) is an I2-set Ig domain; strand D is absent. The loop between the C and Cʹ strands (residues 175-179) is missing due to disorder in the crystals and is shown as a dashed black line. Domain 3 (green) exhibits an I1-set topology25 with two β-sheets, ABED and A′GFC. The A–A′ segmented β-strand, crosses over between B and G respectively. Disulfide bridges connect all B and F strands and are indicated (\*). The N- and C- termini are indicated and are numbered. The right panel shows a monomer of OPCML, with the same color scheme used on the left 3 panels.

**C**



**Supplementary Figure 3. Structure-based multiple sequence alignment of the IgLON family.** Residues conserved across the family are highlighted in black with white lettering. OPCML domain 1 (pink), domain 2 (blue) and domain 3 (green) are shown above the alignment with beta strands as arrows and alpha helices as cylinders. The residues involved in maintaining stacking interaction at the D1-D1 interface are highlighted with red spheres and include Arg 65, Leu 69, Ile 74, Asp 80, Trp 82, Thr 114 and Arg 127 (shown structurally on Figure 1C). The side chains of other residues making contacts at the D1-D1 interface are highlighted with gray triangles and include Ala 67, Arg 71, Ser 72, Thr 73, Ala 77, Ile 84 Ser 116, Gln 118, Pro 123 and Thr 125. Asn 70, residues that make contacts with Asn 70 or to sugar residues attached to Asn 70 are shown with an asterisk (Arg 71, Thr 73, Leu 75, Ser 83, Asp 85, Arg 87, Val 88, Ile 102, Tyr 108, Asp 109 and Tyr 113). These are shown structurally in Supplemental Fig 4. The N-terminal signal sequence and the C-terminal GPI anchor site are not shown for simplicity. Secondary structure for OPCML residues 174-178 are not shown as they are missing in the electron density. The UNIPROT accession numbers for the amino acids used above are given in parentheses followed by percentage sequence identity with OPCML: OPCML (Q14982), NTM (Q9P121, 76%), LSAMP (Q13449, 56%), IGLO5 (A6NGN9, 50%) and NEGR1 (Q7Z3B1, 48%).



**Supplementary Figure 4. Amino acid residues at the D1-D1 interface.** Amino acid residues that make contact with Asn 70 and the NAG-NAG-MAN attached to Asn 70 are shown. D1 from one homodimer is shown in blue space fill and the other D1 as cartoon representation. The NAG-NAG-MAN (shown in green) is covalently attached to Asn 70 and is in stick representation. Other residues involved in contacting Asn 70 and to the sugar residues and shown in stick representation and include Arg 71, Leu 75, Ser 83, Asp 85, Arg 87, Val 88, Ile 102, Tyr 108, Asp 109 and Tyr 113. Thr 73 is out of view. A salt bridge interaction between Arg 87 and Asp 109 are shown by dashed black lines.



Supplementary Figure 5. Packing of OPCML in the crystal lattice. Orthogonal views of OPCML packing interactions as seen in the crystal lattice. The unit cell is shown in both and the OPCML peptide backbone shown as a trace.



**Supplementary Figure 6. Biophysical characterization of WT and point-mutated OPCML.** WT and P95R are predominantly dimeric in solution and R65L is predominately monomeric. **(A)** Gel filtration analysis of WT and OPCML mutants. The elution profiles of WT (red), P95R (blue), R65L (black) and N70H (green) is shown along with molecular weight size standards (in kDa). WT and P95R elute similarly, whilst R65L elutes more slowly. N70H is aggregated. **(B)** The molecular masses of WT, P95R, R65L and N70H (shown in red, blue and black, respectively) were calculated from the elution profile given by SEC-MALS. The calculated masses for WT was 67.3 ±0.2 kDa, P95R 70.1 ±0.2 kDa and R65L 36.2 ±0.1 kDa. OPCML has a molecular mass of approximately 31.7 kDa, as calculated from the primary sequence. **(C)** Concentration dependence of gel filtration profiles for WT (20 nM to 32 μM) and R65L (1 to 32 μM). **(D)** Estimation of monomer-dimer dissociation constant Kd. Peak positions from panel C (circles for WT and triangles for R65L) were fit to an equation describing the monomer-dimer equilibrium (see Methods) showing fit values for WT (95% confidence interval 0.565 to 1.997 μM) and R65L (840 ± 630 μM, 95% confidence interval lower limit 270 μM with no upper limit determined). **(E)** Melting curve profiles for WT, P95R, R65L and N70H (shown in red, blue, black and green respectively) were generated by a SYPRO orange-based thermofluor thermal shift assay. Purified recombinant proteins were heated from room temperature to 95°C, in 0.5°C increments. WT melted at an average of 55.5 °C and P95R 57.0 °C, indicating they have comparable thermal stability. R65L melted at an average of 51.5 °C. All measurements were performed in triplicate. **(F)** SDS PAGE and western blot analysis of purified R65L, N70H, P95R and WT. 0.5 μg of each protein was loaded per lane.





**C)**



**Supplementary Figure 7. OPCML mutants are impaired in migration, invasion and anchorageindependent growth.** SKOV3, PEA1 and PEO1 ovarian cell lines were transduced with an empty vector (CTRL), wild-type (OPCML) or mutant (R65L, N70H and P95R) OPCML and tested for migration **(A)** and invasion **(B)** in transwell assays Representative images of cells that have migrated or invaded, stained with crystal violet. Colonies formed in in agarose following anchorageindependent growth are stained with Red **(C)**.





HCT116



**Supplementary Figure 8. OPCML mutants show impaired tumour suppressor functions in HCT116 cells. (A)** Colorectal HCT116 cells were stably transduced with the indicated constructs and protein expression was verified by immunofluorescence with an anti-OPCML antibody (red). Cell nuclei were stained with DAPI (cyan). Scale bar = 20μm. **(B)** Cells were grown in full medium conditions and their signaling analyzed by western blotting with the indicated antibodies. **(C)** Cells were starved and then stimulated for 3h with Gas6, the interaction of OPCML WT, R65L and P95R with AXL was measured by DuoLink. The graph shows the mean ± s.e.m of 3 independent experiments. Student t-test \*\* p<0.01.

**A) B** 



**Supplementary Figure 9. OPCML interacts with AXL mainly via the D1 domain. (A)** SKOV3 cells were stably transduced with D1, D2 or D3, which are all HA-tagged, and stained in red with an anti-HA antibody. Nuclei are stained by DAPI (cyan). Scale bar = 20μm. **(B)** Cells were grown in full medium and the interaction between the different domains of OPCML and AXL was measured by DuoLink. The number of dots was quantified and graph shows the mean ± s.e.m of 3 independent experiments. **(C)** Cells were starved and then stimulated with Gas6 for 3h. The interaction between OPCML's domains and AXL was measured by DuoLink. The total area covered by the signal was quantified and the graph shows the mean ± s.e.m of 3 independent experiments. Student t-test: \* p<0.05.



Supplementary Figure 10. Incidence and location of the TCGA and COSMIC somatic OPCML mutations mapped onto the structure of OPCML. The somatic OPCML mutations identified from the TCGA and COSMIC databases are mapped on to the secondary structure of OPCML. Shown as a bar chart are the amino acid position (X-axis) and incidence (Y-axis), corresponding to mutations identified in domains 1-3. Domain 1 (salmon, residues 42-134) domain 2 (blue, residues 135-222) and domain 3 (green residues 223-310) are shown. For simplicity, the N-terminal secretion signal and the C-terminal GPI-anchor site are not shown.



**Supplementary Figure 11. D1, D2 and D3 are required to inhibit binding to fibrinogen.** SKOV3 cells transduced with an empty vector (CTRL), wild-type (OPCML) or mutant (R65L, N70H, R71C, P95R, P95L, P95S, E201Q, S203R, R214Q, K230R, K239N, M278I) OPCML were plated onto fibrinogen and adhesion tested after 1h. Values have been normalized to CTRL. The images have been taken with a 2.5x objective. The graph shows the mean ± s.e.m of 3 independent experiments. Student t-test compares CTRL and mutants to wildtype OPCML: \*\*\* p<0.001, \*\*\*\* p<0.0001.



**Supplementary Figure 12. Omit map electron density.** Omit map showing electron density of the D and E β–strands (residues 89-101) which were omitted from the map calculation. Blue mesh represents |2Fo-Fc|\*exp(iαc) electron density, lines represent OPCML model, contoured at 2.0σ.













## **Supplementary Table 1. Mutations identified in cancer patients.** The type of mutation, the location in the domains, the cancer of origin

and the possible effect on the 3D structure are listed as indicated.





**Supplementary Table 2.** Shown are the 6 largest contact areas as seen in the OPCML crystal structure and the buried surface area along with the contact residues and distances involved are listed, within 4 Å. Figures were calculated using PISA. The largest contact surface corresponds to the D1-D1 homodimerization interface and contains 874 Å2 of interface area. The next 5 largest sites comprise consecutively less surface area and fewer amino acid contact sites.